Capsaicin in Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Capsaicin, the major active constituent of chilli, is an agonist on transient receptor potential vanilloid channel 1 (TRPV1). TRPV1 is present on many metabolically active tissues, making it a potentially relevant target for metabolic interventions. Insulin resistance and obesity, being the major components of metabolic syndrome, increase the risk for the development of cardiovascular disease, type 2 diabetes, and non-alcoholic fatty liver disease. In vitro and pre-clinical studies have established the effectiveness of low-dose dietary capsaicin in attenuating metabolic disorders. These responses of capsaicin are mediated through activation of TRPV1, which can then modulate processes such as browning of adipocytes, and activation of metabolic modulators including AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor α (PPARα), uncoupling protein 1 (UCP1), and glucagon-like peptide 1 (GLP-1). Modulation of these pathways by capsaicin can increase fat oxidation, improve insulin sensitivity, decrease body fat, and improve heart and liver function. Identifying suitable ways of administering capsaicin at an effective dose would warrant its clinical use through the activation of TRPV1. This review highlights the mechanistic options to improve metabolic syndrome with capsaicin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Increased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570
Inflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294 · cited 1×
“Many mechanisms have been proposed for the development of insulin resistance, including increased lipid deposition in the tissues [49].”
BackgroundObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Pereira, M. A., Kartashov, A. I., Ebbeling, C. B., Van Horn, L., Slattery, M. L., Jacobs, D. R., & Ludwig, D. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17663-0 · Cited by 1,348
Insulin action and resistance in obesity and type 2 diabetes
Czech, M. P. (2017) · Nature Medicine · doi:10.1038/nm.4350 · Cited by 1,258
Chronic Inflammation in Obesity and the Metabolic Syndrome
Monteiro, R., & Azevedo, I. (2010) · Mediators of Inflammation · doi:10.1155/2010/289645 · Cited by 1,186
Oxidative stress in obesity: A critical component in human diseases
Marseglia, L., Manti, S., D’Angelo, G., Nicotera, A., Parisi, E., Di Rosa, G., Gitto, E., & Arrigo, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010378 · Cited by 933 · cited 1×
“In obesity, adipose tissue inflammation increases the production of reactive oxygen species, which then disturbs the production of adipokines, and can trigger pathology associated with metabolic syndrome [46].”
BackgroundObesity, insulin resistance and free fatty acids
Boden, G. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283444b09 · Cited by 848
Mechanisms of insulin resistance in obesity
Ye, J. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0262-6 · Cited by 699
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 2×
“GLP-1 is an incretin hormone that induces expansion of insulin-secreting β-cell mass; this change augments glucose-stimulated insulin secretion [35].”
BackgroundNon-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564 · cited 1×
“Links have been established between obesity, dyslipidemia, and development of non-alcoholic fatty liver disease [145,146].”
BackgroundThe role of adipose tissue immune cells in obesity and low-grade inflammation
Mraz, M., & Haluzik, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0283 · Cited by 543
Physical Inactivity and Obesity: A Vicious Circle
Pietiläinen, K. H., Kaprio, J., Borg, P., Plasqui, G., Yki‐Järvinen, H., Kujala, U. M., Rose, R. J., Westerterp, K. R., & Rissanen, A. (2008) · Obesity · doi:10.1038/oby.2007.72 · Cited by 388 · cited 1×
“The increasing incidence of obesity, and therefore, of metabolic syndrome, is primarily due to increasing physical inactivity and the increased acquisition of energy from energy-dense or junk foods [57,58].”
BackgroundInflammation and metabolic cardiomyopathy
Nishida, K., & Otsu, K. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx012 · Cited by 329
Lee, S., Gungor, N., Bacha, F., & Arslanian, S. (2007) · Diabetes Care · doi:10.2337/dc07-0203 · Cited by 105
Li, Q., Li, L., Wang, F., Chen, J., Zhao, Y., Wang, P., Nilius, B., Liu, D., & Zhu, Z. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1274-4 · Cited by 91
Cited by
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136
“It was previously described that the L-cells found in the intestine, specifically the ileum and large intestine, and the release of GLP-1 (Törrönen et al., 2012; Yamashita et al., 2013).”
BackgroundInfluentialTRPV1 sustains microglial metabolic reprogramming in Alzheimer's disease
Lu, J., Zhou, W., Dou, F., Wang, C., & Yu, Z. (2021) · The EMBO Reports · doi:10.15252/embr.202052013 · Cited by 121
“Activation of TRPV1 modulates processes such as browning of adipocytes, glucose metabolism of extensor digitorum longus and activation of metabolic modulators such as AMPK, peroxisome proliferator-activated receptor a , uncoupling protein 1, and glucagon-like peptide 1 (Panchal et al, 2018).”
Skeletal muscle non-shivering thermogenesis as an attractive strategy to combat obesity
Li, H., Wang, C., Li, L., & Li, L. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119024 · Cited by 38
Chen, X., Zhang, L., Zheng, L., & Tuo, B. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5169 · Cited by 22
“UCP2 promotes liver β-oxidation and lipid metabolism (74).”
BackgroundInfluential
Metadata
- Authors
- Panchal, S. K., Bliss, E., & Brown, L.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2018-05-17
- Volume
- 10
- Issue
- 5
- Pages
- 630
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2804928201
- Cited by
- 167
- References
- 19
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.